MedPath

Benefits of Unani medicine in common cold

Phase 2
Conditions
Health Condition 1: J309- Allergic rhinitis, unspecified
Registration Number
CTRI/2023/06/053622
Lead Sponsor
ational Institute of Unani Medicine Bangalore
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Age between 18-60 years

2. All genders

3. All cases of allergic rhinitis according to ARIA classification

4. Subjects with both intermittent and/or persistent allergic rhinitis and having at least two of the following rhinitis-associated conditions: nasal congestion, rhinorrhea, sneezing and nasal itching.

5. Patients who will give consent and able to do follow up

Exclusion Criteria

1. Subjects having Nasal polyps, Sinusitis, Atrophic rhinitis, Hypertrophied turbinates,Deviated nasal septum, and congenital nasal abnormalities like nasal dermoid cysts,

congenital midline nasal masses etc.

2. Subjects with a history of heart diseases, kidney diseases, liver diseases, DM,Malignancy, and severe asthma.

3. Subjects who had received systematically or topically administered corticosteroids,

antihistamines, or decongestants 07 days prior to enrolment

4. Personnel who are taking part in other clinical trials

5. Subjects with known allergy from the ingredients of trial interventions

6. Pregnant and lactating women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in Rhino-conjunctivitis Total Symptom Score (RCTSS)Timepoint: 4 weeks
Secondary Outcome Measures
NameTimeMethod
1.Reduction in SNOT-22 score <br/ ><br>2.Improvement in subjective parameters <br/ ><br>3. AECTimepoint: 4 WEEKS
© Copyright 2025. All Rights Reserved by MedPath